Questions for Endeavor
This article was originally published in The Gray Sheet
Executive Summary
European regulatory authorities reviewing a CE mark application for Medtronic's Endeavor drug-eluting stent are requesting further information on the drug compound (ABT-578) supplied by Abbott. Medtronic expects Endeavor to earn European go-ahead after resolution of these "few remaining regulatory questions," the firm says in a May 31 release, acknowledging that regulators have not estimated a timeline for final review. Medtronic previously forecast a CE mark for Endeavor in mid-2005 (1"The Gray Sheet" April 15, 2005, p. 5)...
You may also be interested in...
Carotid Stent, AAA Market Entry: Boston Scientific Moves On Earn-Outs
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.